This technology is an intranasal treatment that can protect against COVID-19 and its variants.
Current methods to prevent the spread of SARS-CoV-2 rely on life-saving vaccines and medications, but as the virus continues to rapidly mutate, vaccinesefficacy decreases. Although additional viral load injections can improve immune defense, there is currently no easy-to-use treatment activating the immune system locally.
This technology is an intranasal injection which activates an immune defense specifically in the nasal cavity. A glyolipid is delivered intranasally to activate T cells, which in turn activate other immune cells and secrete anti-viral cytokines. Through this cascade, the immune system can develop anti-viral properties in the nasal cavity and show prophylactic protection against SARS-CoV-2 infection. This treatment can improve outcomes following COVID-19 but also for other respiratory viruses’ infections.
This technology has been validated with mice.
Patent Pending
IR CU22118
Licensing Contact: Kristin Neuman